Literature DB >> 15150187

Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy.

Alan D Tice1.   

Abstract

Ertapenem is a parenteral carbapenem antimicrobial with pharmacological properties that allow it to be given once daily. This makes it a consideration for outpatient parenteral antimicrobial therapy (OPAT). In comparison with information from the OPAT Outcomes Registry, ertapenem seems well suited for the types of infections and bacteria that are commonly treated with OPAT, plus it has additional activity against anaerobic bacteria. This added spectrum makes it possible to treat complicated skin/skin-structure, complicated intra-abdominal and pelvic infections with a single antibiotic instead of the multiple agents that have usually been required. Ertapenem is also comparable to other OPAT antimicrobials in terms of adverse effects and clinical outcomes. This antimicrobial can be given with any delivery model, although its stability when mixed is such that daily preparation or self-mixing systems need to be considered. Ertapenem should be added to the growing list of once-daily parenteral antibiotics that can be given to outpatients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15150187     DOI: 10.1093/jac/dkh210

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  New drugs to treat skin and soft tissue infections.

Authors:  Gary E Stein
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

2.  Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Authors:  Vicki L Collins; Dror Marchaim; Jason M Pogue; Judy Moshos; Suchitha Bheemreddy; Bharath Sunkara; Alex Shallal; Neelu Chugh; Sara Eiseler; Pragati Bhargava; Christopher Blunden; Paul R Lephart; Babar Irfan Memon; Kayoko Hayakawa; Odaliz Abreu-Lanfranco; Teena Chopra; L Silvia Munoz-Price; Yehuda Carmeli; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

3.  How much money can be saved by applying intravenous antibiotics once instead of several times a day?

Authors:  D Mertz; H Plagge; S Bassetti; M Battegay; A F Widmer
Journal:  Infection       Date:  2010-10-28       Impact factor: 3.553

4.  Stability of Ertapenem 100 mg/mL in Manufacturer's Glass Vials or Syringes at 4°C and 23°C.

Authors:  Scott E Walker; Shirley Law; William Perks; John Iazzetta
Journal:  Can J Hosp Pharm       Date:  2015 Mar-Apr

Review 5.  Ertapenem: a review of its use in the treatment of bacterial infections.

Authors:  Gillian M Keating; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Ertapenem for treatment of osteomyelitis: a case series.

Authors:  Neela D Goswami; Melissa D Johnson; Vivian H Chu
Journal:  BMC Res Notes       Date:  2011-11-02

7.  In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.

Authors:  Matthew Gethers; Iris Chen; Kamilia Abdelraouf; David P Nicolau
Journal:  J Antimicrob Chemother       Date:  2022-06-29       Impact factor: 5.758

8.  Efficacy and Cost Comparison of Ertapenem as Outpatient Parenteral Antimicrobial Therapy in Acute Pyelonephritis due to Extended-spectrum Beta-lactamase-producing Enterobacteriaceae.

Authors:  V Ramasubramanian; P Murlidharan; S Nambi; S Pavithra; S Puthran; T Petigara
Journal:  Indian J Nephrol       Date:  2018 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.